Underpowered PANTS: A Response to the Conclusions of "Extended Analysis Identifies Drug-Specific Association of Two Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab"

Gastroenterology. 2021 Jan;160(1):470-471. doi: 10.1053/j.gastro.2020.05.102. Epub 2020 Oct 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adalimumab
  • Crohn Disease* / drug therapy
  • Crohn Disease* / genetics
  • Haplotypes
  • Humans
  • Infliximab
  • Pharmaceutical Preparations*
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Pharmaceutical Preparations
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Adalimumab